![Moderate to Severe Hidradenitis Suppurativa Successfully Treated With Secukinumab | Actas Dermo-Sifiliográficas Moderate to Severe Hidradenitis Suppurativa Successfully Treated With Secukinumab | Actas Dermo-Sifiliográficas](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S1578219020302626:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w91sAmkCw32Jed9sZf6jzEuDbFpW7G0NfARZs8afh+9K8v8RN+oFy2ZmalFHXVYo6AiTTXm8KNZD0h/m4bQ5x/lPAay+lhdWxvnX7scpmxMcxzl25qIOmN+ZkbyoMlIW7qCeP/91JhJkRyaEBWen2xmNaW9yXK+vynouqKklBKMaqdMfvuGgOqZ8N6dbYVaH3/Ea4FOFpYDJmORDEllSDBAgV6qIa13g3VV+Zq+x8+3I853G3j53LS1360lrgIIchy1yVYAXaSMsoRPfMGQT2wc8=)
Moderate to Severe Hidradenitis Suppurativa Successfully Treated With Secukinumab | Actas Dermo-Sifiliográficas
![PDF) Repurposing of Secukinumab as Neuroprotective in Cuprizone-Induced Multiple Sclerosis Experimental Model via Inhibition of Oxidative, Inflammatory, and Neurodegenerative Signaling PDF) Repurposing of Secukinumab as Neuroprotective in Cuprizone-Induced Multiple Sclerosis Experimental Model via Inhibition of Oxidative, Inflammatory, and Neurodegenerative Signaling](https://i1.rgstatic.net/publication/342017796_Repurposing_of_Secukinumab_as_Neuroprotective_in_Cuprizone-Induced_Multiple_Sclerosis_Experimental_Model_via_Inhibition_of_Oxidative_Inflammatory_and_Neurodegenerative_Signaling/links/5ee4d5a6a6fdcc73be781f37/largepreview.png)
PDF) Repurposing of Secukinumab as Neuroprotective in Cuprizone-Induced Multiple Sclerosis Experimental Model via Inhibition of Oxidative, Inflammatory, and Neurodegenerative Signaling
![Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2667026721000965-gr4.jpg)
Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect
![COSENTYX 150 MG INJEKČNÝ ROZTOK V NAPLNENEJ INJEKČNEJ STRIEKAČKE sol inj 1x1 ml/150 mg (striek.inj.skl.) - Príbalový leták COSENTYX 150 MG INJEKČNÝ ROZTOK V NAPLNENEJ INJEKČNEJ STRIEKAČKE sol inj 1x1 ml/150 mg (striek.inj.skl.) - Príbalový leták](https://www.liekinfo.sk/PublicData/Liekinfo/Leaflets/cosentyx_soubory/image029.png)
COSENTYX 150 MG INJEKČNÝ ROZTOK V NAPLNENEJ INJEKČNEJ STRIEKAČKE sol inj 1x1 ml/150 mg (striek.inj.skl.) - Príbalový leták
Cosentyx Novartis. Mi experiencia. - Hoy toca vacunarse! La verdad estas vacunas son una maravilla. A penas tengo un poco de brote en la cabeza pero el resto del cuerpo perfecto. | Facebook
![Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis | Actas Dermo-Sifiliográficas Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis | Actas Dermo-Sifiliográficas](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S1578219018301628:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w91sAmkCw32Jed9sZf6jzEuDbFpW7G0NfARZs8afh+9K8v8RN+oFy2ZmalFHXVYo6ApjxQWIANA6Unj9lDpPa+rQM7jhKEBvwdGVMaFaOln4oTSuZvUdd7h2kwO+YdyDqbvR1Q7tBEnE8ib+fW15cmpGDm0c6SpK0kSxN5KZzIvEuyPimr53u5Txx8XdB7KirwuR1mnIcyW+WTRgMIWinPV2m+gmwlCkiDX7e/rzeB1EcW65kO5G/aIy2I2he7vLzEVvYs26EEizyeBS+t4/aH6g=)
Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis | Actas Dermo-Sifiliográficas
![COSENTYX 150 MG INJEKČNÝ ROZTOK V NAPLNENEJ INJEKČNEJ STRIEKAČKE sol inj 1x1 ml/150 mg (striek.inj.skl.) - Príbalový leták COSENTYX 150 MG INJEKČNÝ ROZTOK V NAPLNENEJ INJEKČNEJ STRIEKAČKE sol inj 1x1 ml/150 mg (striek.inj.skl.) - Príbalový leták](https://www.liekinfo.sk/PublicData/Liekinfo/Leaflets/cosentyx_soubory/image039.png)
COSENTYX 150 MG INJEKČNÝ ROZTOK V NAPLNENEJ INJEKČNEJ STRIEKAČKE sol inj 1x1 ml/150 mg (striek.inj.skl.) - Príbalový leták
![Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2667026721000965-gr6e.jpg)
Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect
Cosentyx® Novartis Biociências SA Solução injetável 150 mg/mL Contém: 1 ou 2 canetas preenchidas Bula do Paciente
![A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis | Reumatología Clínica A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis | Reumatología Clínica](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S1699258X20301327:gr2.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9184xd8ym1IgxXJ6I4p31f1upH6Ra9/FExf9t4wRA9EIriUoQSJ7fSidwwowDcP4rwo9eewov7++gyK1yIOWWg8MiulrTcKaRgl0JB+dCIKUa8o/VrkPZODamXQa9hSHyTjtu/dYFv5FhEUm/S6xBlVt3Pap8WRuOBcGGIpJcplGauIQ8A6Tv9Kznn5Q91dN6t8vBckUVJI8AQw3TX9Xs7n+SAon2wpjRxDEj6oyCg+zNqxBFpPvUpHT+EmgonA8GF4TwU00Umq36c6h13cnIK0=)
A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis | Reumatología Clínica
![A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis | Reumatología Clínica A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis | Reumatología Clínica](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S1699258X20301327:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9184xd8ym1IgxXJ6I4p31f1upH6Ra9/FExf9t4wRA9EIriUoQSJ7fSidwwowDcP4rwo9eewov7++gyK1yIOWWg8MiulrTcKaRgl0JB+dCIKUa8o/VrkPZODamXQa9hSHyTjtu/dYFv5FhEUm/S6xBlVt3Pap8WRuOBcGGIpJcplGauIQ8A6Tv9Kznn5Q91dN6t8vBckUVJI8AQw3TX9Xs7n+SAon2wpjRxDEj6oyCg+zNqxBFpPvUpHT+EmgonA8GF4TwU00Umq36c6h13cnIK0=)
A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis | Reumatología Clínica
![Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2667026721000965-gr3.jpg)
Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect
![Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2667026721000965-gr2.jpg)
Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect
![Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2667026721000965-gr5.jpg)